M Jamei

A Physiologically –Based Pharmacokinetic Modelling Approach to Predict Disease-Drug Interactions: Suppression of CYP3A by IL-6.

Framework, Organization and Applications of the Simcyp Population-Based Simulator to Support New Drug Development

An assessment of the OCT2/MATE transporter mediated DDI between metformin and cimetidine using a Mechanistic Kidney model (Mech KiM)

An in silico PBPK-PD coupled approach to assess zolpidem effect on pre-clinically and clinically measured cardiac repolarisation parameters in the absence and presence of a circadian model of plasma ion concentration

Towards more Realistic Clinical Trial Simulation: Establishing Inter-Correlations between Several Cytochrome P450 Enzyme Abundances in Human Liver

Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism Application of Permeability-Limited Physiologically-Based Pharmacokinetic Models: Part I-Digoxin Pharmacokinetics Incorporating P-Glycoprotein-Mediated Efflux

Prediction of skin disposition after topical application of drugs – Simcyp platform as a tool for capturing system information and safety assessment

Prediction of QT changes in humans incorporating in vitro data into physiologically based cardiomyocyte cell model – a case study on inhibition of multiple cardiac ion currents by tolterodine and its metabolite

Prediction of Passive Regional Effective Intestinal Permeability in Mouse using ?MechPeff?: A Mechanistic Model utilizing only Drug Physiochemical Parameters as Inputs

PBPK modeling of Negative Food Effects upon Oral Drug Absorption of the BCS Class III Drug Trospium Chloride (TC): Combination of a Dynamic Viscosity-Disintegration Model and the ADAM (Advanced Dissolution, Absorption and Metabolism